Mayne Pharma (ASX:MYX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Mayne Pharma (ASX:MYX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
2026 Notice of Annual General Meeting and shareholder pack
MYX settles US patent litigation re Imvexxy with Teva USA
Mayne Pharma settles Teva IMVEXXY patent litigation with generic entry set for 2032
Supreme Court Decision in Cosette Proceedings
Trading Halt
Fulfilment of Imvexxy post-marketing study requirements
Notification of cessation of securities - MYX
MYX settles US patent litigation re Imvexxy with Sun Pharma
Mayne Pharma settles IMVEXXY patent litigation with Sun Pharma, setting generic entry for 2032
Mayne Pharma announces legal settlement
Date for Annual General Meeting
MYX signs licence agreement for Blissel in Australia
Notification of cessation of securities - MYX
Notification regarding unquoted securities - MYX
Application for quotation of securities - MYX
2026 Full Year Results Investor Presentation
Mayne Pharma FY26 revenue down 6%, underlying EBITDA down 27%, strong DistributeRx launch
2026 Corporate Governance Statement and Appendix 4G
2026 Full Year Results Media Release
Mayne Pharma FY26 revenue down 6% with strong Women's Health growth and DistributeRx launch
2026 Appendix 4E and Annual Report
Mayne Pharma returns to profit with $24.5 million net income in FY2026 on lower revenue
Notification of date for release of FY26 results
Upcoming presentation of Imvexxy clinical data
Mayne Pharma launches Investor Hub
Initial Director's Interest Notice
Mayne Pharma Bioshares Summit Presentation
Notification of cessation of securities - MYX
Notification regarding unquoted securities - MYX
Non-Executive Director appointment
Mayne Pharma to present at the 20th Bioshares Summit
Mayne Pharma reports unaudited Q4 and FY26 results
Mayne Pharma reports 6% revenue decline in FY26 with strong Women’s Health growth and DistributeRx expansion